PainChek Ltd (AU:PCK) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
PainChek Ltd is experiencing significant growth with a 10% increase in implemented licenses, driven by new contracts and training methods. The company has secured funding from the Western Australian government for a new app to assess pain in non-verbal children with disabilities, and is conducting a live trial at the Royal Infirmary of Edinburgh. These developments position PainChek to expand its market presence and enhance its advanced pain assessment solutions.
For further insights into AU:PCK stock, check out TipRanks’ Stock Analysis page.